BioAffinity Technologies Appoints Two New Board Members, Expands Expertise

• bioAffinity Technologies appoints Roberto Rios, CPA, and John J. Oppenheimer, M.D. to Board of Directors • Rios brings 4 decades of corporate finance and business expertise • Oppenheimer brings clinical leadership experience • Appointments expected to enhance company's commercial growth • bioAffinity Technologies advances noninvasive diagnostics for lung cancer and other diseases • CyPath Lung sales expected to increase with new appointments • Companion diagnostics for asthma and COPD to be developed • Financial position to be strengthened with new Board members.

SAN ANTONIO, Texas — BioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company specializing in noninvasive diagnostics for early detection of lung cancer and other diseases, has announced the appointment of Roberto Rios, CPA, and John J. Oppenheimer, M.D., to its Board of Directors. The appointments aim to enhance the company's commercial growth and strengthen its financial position.

Roberto Rios brings over four decades of executive leadership in corporate finance and governance across various industries, including biotechnology, medical devices, and large-scale construction. He has held financial leadership roles at ILEX Oncology, BioMedical Enterprises, and Bartlett Cocke General Contractors, and currently serves on the boards of CCC Group and Stem Cell Reserve. His extensive experience in guiding companies through growth, capital strategy, and operational excellence will bolster bioAffinity Technologies' financial foundation [1].

Dr. John J. Oppenheimer, the Director of Clinical Research at Pulmonary and Allergy Associates and Clinical Professor of Medicine at the University of Medicine and Dentistry of New Jersey-Rutgers, is a leader in the diagnosis and treatment of asthma and COPD. He has participated in over 180 clinical studies and authored more than 260 publications, contributing significantly to clinical guidelines. His extensive clinical experience will help guide bioAffinity's scientific and clinical strategies, particularly in developing companion diagnostics for asthma and COPD, a growing market estimated at $26 billion [2].

The appointments come as bioAffinity Technologies seeks to increase sales of its flagship product, CyPath® Lung, and strengthen its financial position. CyPath® Lung uses advanced flow cytometry and artificial intelligence to identify cell populations in patient sputum that indicate malignancy. Clinical study results demonstrated high sensitivity (92%), specificity (87%), and accuracy (88%) in detecting lung cancer in high-risk patients with small lung nodules [1].

The company also announced that Gary Rubin stepped down from the Board of Directors for personal reasons. "We are grateful to Gary for his valuable contributions to bioAffinity over the past seven years and appreciate his continued support," said Maria Zannes, President and CEO of bioAffinity Technologies [1].

References:
[1] https://finance.yahoo.com/news/bioaffinity-technologies-appoints-members-board-120000250.html
[2] https://www.stocktitan.net/news/BIAF/bio-affinity-technologies-appoints-new-members-to-board-of-whrunytyh5xb.html